Inhaled flecanide developer InCarda Therapeutics has named former Arena Pharmaceuticals executive Robert Lisicki as CEO, succeeding Grace Colón who the company says “intends to pursue other leadership opportunities within the life science space” but will continue to consult for InCarda. In addition to having served as Chief Commercial Officer at Arena, Lisicki previously served in executive positions at Regeneron, Daiichi-Sanyko, and Amgen.
Lisicki commented, “I am excited to take the reins at InCarda and continue the company’s efforts to bring a transformative inhaled treatment to the millions of people in the US and around the world who are living with atrial fibrillation. The company is in a strong position for success highlighted by its talented team and an ongoing pivotal Phase 3 trial of InRhythm, a first-of-its-kind inhaled therapy for the potential treatment of paroxysmal atrial fibrillation. I look forward to drawing upon my commercial, operational, and public company experience to help continue InCarda’s positive trajectory, while scaling the company in preparation for its next growth phase.”
Colon said, “I would like to congratulate Rob, and I share the board’s excitement for the impact he will have on leading InCarda into its next stage. I look forward to supporting him and ensuring a seamless transition. I would like to thank the InCarda family for making my time with the company a fantastic experience and I am proud of all we achieved over the last ten years. While I look forward to moving on and pursuing other leadership opportunities, I am just as excited to see the team continue to advance the mission of bringing groundbreaking therapies to patients.”
Read the InCarda Therapeutics press release.
